Evolus, Inc. (EOLS) Social Stream



Evolus, Inc. (EOLS): $11.69

0.09 (+0.78%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Evolus Inc (EOLS) Price Targets From Analysts

The tables below show price targets and recommendations from analysts covering Evolus Inc.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2022-01-13 7 $20 $7 $15.142 $11.06 36.91%
2022-01-27 6 $20 $7 $15.142 $11.06 36.91%
2022-03-04 7 $20 $7 $15.428 $11.06 39.49%

The Trend in the Analyst Price Target


Over the past 21 months, EOLS's average price target has gone up $0.39.

Over the past 48 weeks, EOLS's average upside potential has been 77.57%.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2021-05-15 8 30 4 17.110 9.06 88.85%
2021-08-14 8 25 4 15.500 10.60 46.23%
2021-11-04 7 20 7 15.142 7.23 109.43%
2022-03-04 7 20 7 15.428 9.53 61.89%
2022-03-04 7 20 7 15.142 9.53 58.89%

EOLS Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1.57 6 0 0 1 1 7

The Trend in the Broker Recommendations


Over the past 120 days, EOLS's average broker recommendation rating improved by 0.29.

The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for EOLS as an investment opportunity.

  • In terms of how Evolus Inc fares relative to all US stocks, note that its variance in analysts' estimates is lower than -165.12% of that group.
  • In the context of all US stocks, Evolus Inc's average analyst price target is higher than 48.96% of them.
  • Evolus Inc's number of analysts covering the stock is greater than 250.9% of stocks in the small market cap category.
  • Evolus Inc's upside potential (average analyst target price relative to current price) is higher than 51.55% of Pharmaceutical Products stocks.

Stocks similar to Evolus Inc in the Pharmaceutical Products industry regarding analyst recommendations and price targets are ENSC, ENOB, and ELYM.

What is the outlook for EOLS? Use POWR Ratings for clearer insight into price direction.


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4515 seconds.